Stratvocate offers a wealth of information and easy-to-use tools for those involved in federal contracting.

Subject: Notice of Intent to issue a Sole Source Award to generate and optimize high-affinity nucleic acid aptamers capable of semi-quantitative detection of TFV-DP and/or TFV for use in both plate-based assays and POC platforms.
Solicitation Number: 75D30126R73457
Notice Type: PRESOL
NAICS: 541715
Set-Aside: No Set aside used
Notice Published: 05-18-26
Response Due: 06-02-26

Agency: Department of Health and Human Services
Office: CENTERS FOR DISEASE CONTROL AND PREVENTION
Contact: Eugene L. Gutierrez Jr. This email address is being protected from spambots. You need JavaScript enabled to view it. Ph: (770) 488-0192
Office Address: ATLANTA, GA 30333
Place of Performance: Chapel Hill, NC 27599


Click for official SAM (FBO) notice, additional information, and accompanying attachments

The Centers for Disease Control and Prevention Division of HIV Prevention (DHP)/Laboratory Branch intends to award a sole source Firm-fixed-price purchase order to the University of North Carolina at Chapel Hill, Department of Chemistry to generate and optimize high-affinity nucleic acid aptamers capable of semi-quantitative detection of TFV-DP and/or TFV for use in both plate-based assays and POC platforms. This contract action is for commercial services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 12.102-1. NAICS 541715 - Medical Research and Development Laboratories or Services (except Biotechnology and Nanotechnology Research and Development). UNC was identified as uniquely qualified due to its role as a co-inventor of the FTC aptamer previously developed for ARV detection research, and established methodologies compatible with CDC’s current assay development efforts. UNC is the only source reasonably available capable of performing the required work within the required timeframe and technical specifications. Changing to another vendor’s aptamer would severely impact the CDC’s progress in this area, requiring a start over of the entire process of optimization and would not be compatible with the already developed, existing aptamer detecting emtricitabine. This notice of intent is not a request for competitive quotations; however, all Quotations/ responses received within 15 days of the issuance of this notice shall be considered by the government. A determination by the government not to complete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to the contract specialist at email This email address is being protected from spambots. You need JavaScript enabled to view it. by 06/02/2026.